West Pharma (WST) Tops Q2 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
West Announces Second Quarter 2016 Results
July 28, 2016 7:01 AM EDTEXTON, Pa., July 28, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second quarter 2016 and updated financial guidance for the full-year 2016.Â
Second Quarter 2016 Highlights
Reported net sales of $388.0 million grew 7.9% over the prior-year quarter. Net sales at constant currency grew by 8.2%. Second quarter 2016 reported diluted EPS was $0.60 as compared to $0.38 in the prior-year quarter. Excluding restructuring and retirement charges from both periods, adjusted diluted EPS was... More